Although antimicrobial agents are eflective therapy for early Lyme disease, optimal treatment schedules have not been conclusively established. The efficacy of various dosages of eight antibiotics used for borreliosis treatment was evaluated for C3H/HeNCrlBR mice, which reproducibly develop persistent infection, arthritis, and carditis when inoculated with Borrelia burgdorfieri. Amoxicillin-clavulanic acid, ceftriaxone, and high-dose penicillin G effectively eliminated infection and disease. Oxytetracycline, doxycycline, chloramphenicol, erythromycin, and azithromycin failed to cure infected mice. There was a correlation between peak serum antibiotic concentrations in mice, as determined by agar well diffusion bioassays, and therapeutic levels in humans. When experimentally inoculated mice were treated at 1 week postinfection with ceftriaxone (16 mg/kg of body weight twice daily for 5 days) and monitored for up to 90 days, all treated mice were free of spirochetes and had no gross or histologic lesions. This antibiotic regimen at days 7 to 11 postinoculation eliminated the spirochetes so that there were no relapses during the 90-day observation period.' For experimentally inoculated mice treated with ceftriaxone at 7 or 14 days postinfection, arthritis, carditis, and infection were eliminated. When treatment began at 30 and'90 days after inoculation, infection and active cardiac and arthritic lesions were eradicated; however, residual mild synovitis and vasculitis persisted in some mice. In comparison with inoculated, untreated mice, ceftriaxone therapy at 7, 14, 30, and 90 days postinfection abrogated the development of antibody titers against B. burgdorferi. Having the potential to determine the presence of the spirochete through culture and histologic lesions makes the B. burgdorferi-inoculated C3H mouse model a valuable adjunct in evaluating chemotherapeutic options for Lyme disease.
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Caused by the tick-borne spirochete, Borrelia burgdorferi, Lyme disease elicits a wide array of clinical disorders in humans and domestic animals worldwide. Initially presenting with a characteristic rash (erythema migrans), untreated patients with Lyme borreliosis may subsequently develop neurologic disease, cardiac conduction abnormalities, or arthritis (50) .
Although antibiotics are known to be effective in treating early Lyme disease, optimal treatment regimens have not been definitively established. Treatment recommendations are often based on stage of disease at presentation. Currently, the most commonly prescribed oral antibiotics for early Lyme disease include doxycycline, amoxicillin, and erythromycin (26, 43, 44) . Late Lyme disease can be refractory to oral antimicrobial therapy; patients often receive parenteral penicillin or ceftriaxone (13, 26, 43, 44) . Clinical Lyme disease is often characterized by a pattern of relapses and remissions; reinfection has also been described (36) . This clinical picture in conjunction with the difficulties in confirming a diagnosis of Lyme disease also means that it is impossible'to ascertain whether antimicrobial treatment has been truly successful.
To evaluate the effectiveness of antimicrobial therapy in a controlled environment, several laboratory animal models of Lyme disease have been studied. Hamsters (22) (23) (24) and gerbils (33, 41) have been used to assess the in vivo effectiveness of selected antibiotics against B. burgdorferi. In both situations, once-daily dosage schedules were used and culture results alone were used to determine clearance of B. burgdorferi. We have developed a mouse model for Lyme borreliosis in which C3H/HeNCrlBR (C3H) mice reproducibly develop infection and disease (arthritis and carditis) following intradermal (i.d.) inoculation with B. burgdorferi (3, 5) . This study was undertaken to evaluate the effectiveness of eight antibiotic treatment regimens for eradicating B. burgdorferi infection and disease in infected mice. To evaluate systemic antibiotic absorption in treated mice, serum antibiotic concentrations were determined by an agar well diffusion bioassay. The second objective was to determine if the most effective antibiotic regimen was truly curative, as determined by examination for infection and lesions at various intervals posttreatment. The final goal was to evaluate the effectiveness of antimicrobial treatment in arresting lesion progression when the treatment was initiated at extended intervals postinfection.
MATERIALS AND METHODS
Mice. Three-week-old, specific-pathogen-free C3H mice were purchased from Charles River Laboratories (Raleigh, N.C.), shipped in filtered crates, and housed in Micro-Isolator cages (Lab Products, Maywood, N.J.). Autoclaved food (Agway, Syracuse, N.Y.) and water were provided ad libitum. Experimental protocols were initiated within 10 days after arrival. At the end of each experiment, the mice were killed with carbon dioxide and exsanguinated by cardiocentesis.
B. burgdorferi. The N40 isolate of B. burgdorferi was used. It is a low-passage (P2) tick isolate from Westchester County, N.Y., with proven pathogenicity in laboratory rodents and rabbits (7, 31, 32) . The isolate was grown in modified Barbour- Stoenner-Kelly (BSK II) medium (2) (3) . At necropsy, ear punch biopsies and 0.5 ml of 10% (wtlvol) homogenate of spleen from each mouse were cultured in 7 ml of BSK II medium (2) . After incubation at 35°C for 14 days, cultures were examined for spirochetes by dark-field microscopy. We had previously determined that these two culture sites are adequate to determine the presence of spirochetes in infected mice when monitored for up to 1 year (6). Brain tissue is inconsistently culture positive and only in the earliest stages of infection, even in severe combined immunodeficient mice (6, 8) .
Antimicrobial (Tables 1 and 2 ). Erythromycin, oxytetracycline, and doxycycline all failed to eliminate infection and disease. Both chloramphenicol and azithromycin failed to cure infected mice; however, histologic lesion development for both therapies was milder at the higher dosage schedules. We chose ceftriaxone for later stages of this study to avoid potentially inconsistent absorption associated with oral amoxicillin-clavulanic acid administration.
The agar well diffusion bioassay was used to determine serum antibiotic concentrations in mice at 15, 30, 60 , and 120 min posttreatment with the highest dose of each antibiotic (Table 3) . Serum antibiotic concentrations met or exceeded reported peak serum concentration in humans for penicillin G, amoxicillin, ceftriaxone, doxycycline, erythromycin, and azithromycin, indicating that systemic absorption of these drugs had occurred in treated mice.
We appears to be more effective than penicillin, with sporadic successes reported with chloramphenicol and tetracyclines (1, 16, 28) . Since B. burgdorferi is killed slowly, it appears that prolonged elevated antimicrobial levels are required to eradicate infection (28, 34) .
In vitro susceptibility studies indicate that erythromycin, amoxicillin, amoxicillin-clavulanic acid, tetracyclines, ceftriaxone, and azithromycin have high activity against B. burgdorferi, with generally low activity reported for penicillin G (15, 23-25, 33, 40, 41, 45) . However, in vitro results have no proven correlation with antimicrobial clinical effectiveness in vivo (49, 57) , since the relationship of MICs or MBCs of drugs against slowly dividing organisms such as B. burgdorferi and in vivo efficacy has not yet been established (26) . In addition, in vitro antibiotic susceptibility testing is not standardized, and for at least one antibiotic (penicillin), poor in vitro performance is a result of the drug's instability in the spirochete medium rather than low activity against the parasite (14) .
Previous animal model studies have indicated that amoxicillin-clavulanic acid, ceftriaxone, tetracycline, and azithromycin are more active than penicillin in eliminating spirochetal infection from gerbils and hamsters (22-24, 33, 39, 41) . Many of these studies have limited applicability, since culture alone was used as the criterion for spirochetal eradication. Histopathologic analyses were not performed with the hamsters or gerbils, since these species do not develop significant lesions when infected with B. burgdorferi (17, 38) . A further disadvantage of these studies is that once-daily dosing schedules were used, regardless of the pharmacokinetics of each antibiotic.
In the present study, the beta-lactam antibiotics (amoxicillinclavulanic acid, ceftriaxone, and high-dose penicillin G) were most effective at eliminating infection, carditis, and arthritis in experimentally inoculated mice. All three of these antibiotics achieved peak serum concentrations greater than or equivalent to human treatment values (29, 35) . Once-daily penicillin therapy for 5 or 7 days failed to eliminate infection in experimentally infected hamsters and gerbils (22, 24, 33) ; however, similar doses given four times daily were effective in the mice of this study and in gerbils treated three times daily for 10 days (21), indicating that frequency of administration can be a significant variable in animal studies.
Although the tetracyclines are commonly prescribed for human Lyme disease patients, their efficacy in infected mice was poor. Treatment for up to 14 days with doxycycline resulted in abatement of gross joint enlargement; however, there was no significant effect in abrogating development of histologic arthritis or carditis. For oxytetracycline, peak serum ANTIMICROBIAL TREATMENT OF B. BURGDORFERI IN MICE 1571 concentrations were well below that of humans. In rats, low serum tetracycline concentrations were also reported following oral administration. It has been suggested that there is limited gastrointestinal absorption of this antibiotic in rats (and possibly mice), which may limit systemic efficacy (37) . Mice treated with doxycycline had serum antibiotic concentrations comparable to those of humans at 15 min. This expanded-spectrum tetracycline has greater lipid solubility than other tetracyclines, which may account for more-efficient absorption after oral administration (46, 48) . Although we demonstrated systemic absorption of doxycycline, clearance of infection and disease in inoculated mice did not occur.
Chloramphenicol at the higher dose was moderately efficacious in eliminating infection and disease from over half of the inoculated mice. Peak serum concentrations, however, were well below those reported for humans.
Erythromycin was ineffective in eliminating infection or disease in B. burgdorferi-inoculated mice. Despite having high in vitro efficacy against the spirochete, it has not shown significant in vivo efficacy in hamsters or gerbils (22, 33) . Erythromycin has also been less effective in humans with Lyme disease, although it is an alternative treatment for the penicillin-or tetracycline-allergic patient (42) . Azithromycin is a new azalide antibiotic structurally related to erythromycin. It is effective in eliminating B. burgdorfen infection in hamsters (23) and gerbils (39, 41) and has shown promise because of its high tissue concentrations and once-daily dosing (18) . Preliminary studies of patients with early Lyme disease indicate that azithromycin eradicates erythema migrans more quickly than doxycycline; however, B. burgdorfen persists in the skin for up to 3 months after treatment (55) . Azithromycin has also been shown to be less effective than amoxicillin for erythema migrans treatment in one study (27) ; however, a comparison of azithromycin, doxycycline, or amoxicillin plus probenecid showed similar efficacy for the three regimens (30) . A related azalide antibiotic, roxithromycin, was effective in eliminating infection from gerbils but failed in humans (20) . In the present study, azithromycin at up to 10 times the total recommended human dose failed to eliminate infection or disease in experimentally inoculated mice, despite attainment of adequate therapeutic serum concentration at 15 min.
The MICs and MBCs of the 8 antimicrobial agents against the N40 strain of B. burgdorfen were not determined; however, other in vitro studies indicate that geographically disparate strains of B. burgdorferi are similar in their antimicrobial susceptibility patterns (40, 45) . Although we have demonstrated in this study a correlation between peak serum concentrations of antibiotics in mice and therapeutic concentrations in humans, it should be noted that samples were obtained from uninfected mice. Infection with B. burgdorferi could be a complicating factor affecting the renal handling, pharmacokinetics, and resultant serum concentrations of these drugs.
Treatment failures are documented for all antibiotics used in Lyme disease patients. Reasons for these failures include sequestering of the organism in sites inaccessible to the antibiotic (19, 50) , patient genetic predisposition to chronic Lyme disease (51) , the presence of inflammatory mediators mimicking the signs of active Lyme disease, the placebo effect of antibiotic treatment (42) , inadequate duration of antimicrobial treatment (11) , and, perhaps most frequently, incorrect diagnosis (41, 50) . In this study, we evaluated whether ceftriaxone could produce a microbiologic cure when administered early in the course of infection with a 90-day follow-up. Within the observation period, there was no evidence of recrudescence of infection or disease in any of the mice, suggesting that ceftriaxone effectively eliminated the spirochete. This finding has been useful in ongoing studies of reinfection in this model (4, 6 
